Jaimie D Nathan

Dr. Jaimie D Nathan

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KMKyu Shik Mun
Kyu Shik Mun
KAKavisha Arora
Kavisha Arora
YHYunjie Huang
Yunjie Huang
FYFanmuyi Yang
Fanmuyi Yang
SYSunitha Yarlagadda
Sunitha Yarlagadda
ANAnjaparavanda Naren
Anjaparavanda Naren
Cystic fibrosis (CF) is a genetic disorder caused by defective CF Transmembrane Conductance Regulator (CFTR) function. Insulin producing pancreatic islets are located in close proximity to the pancreatic duct and there is a possibility of impaired cell-cell signaling between pancreatic ductal epithelial cells (PDECs) and islet cells as causative in CF. To study this possibility, we present an in vitro co-culturing system, pancreas-on-a-chip. Furthermore, we present an efficient method to micro dissect patient-derived human pancreatic ducts from pancreatic remnant cell pellets, followed by the isolation of PDECs. Here we show that defective CFTR function in PDECs directly reduced insulin secretion in islet cells significantly. This uniquely developed pancreatic function monitoring tool will help to study CF-related disorders in vitro, as a system to monitor cell-cell functional interaction of PDECs and pancreatic islets, characterize appropriate therapeutic measures and further our understanding of pancreatic function.

23 September 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
FDFrank DiPaola
Frank DiPaola
ATAndrew T. Trout
Andrew T. Trout
AWAshley E. Walther
Ashley E. Walther
AGAnita Gupta
Anita Gupta
RSRachel Sheridan
Rachel Sheridan
JNJaimie D Nathan
Jaimie D Nathan


1 September 2018 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
ILInna N. Lobeck
Inna N. Lobeck
AAAmir M. Alhajjat
Amir M. Alhajjat
PDPhylicia Dupree
Phylicia Dupree
JRJohn M. Racadio
John M. Racadio
MMMark M. Mitsnefes
Mark M. Mitsnefes
JNJaimie D Nathan
Jaimie D Nathan

25 November 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
KPKelli N. Patterson
Kelli N. Patterson
ATAndrew T. Trout
Andrew T. Trout
ASArchana Shenoy
Archana Shenoy
MAMaisam Abu-El-Haija
Maisam Abu-El-Haija
JNJaimie D Nathan
Jaimie D Nathan
Pancreatic tumors in children are infrequently encountered in clinical practice. Their non-specific clinical presentation and overlapping imaging characteristics often make an accurate preoperative diagnosis difficult. Tumors are categorized as epithelial or non-epithelial, with epithelial tumors further classified as tumors of the exocrine or endocrine pancreas. Although both are tumors of the exocrine pancreas, solid pseudopapillary neoplasm is the most prevalent solid pancreatic tumor in children, while pancreatoblastoma is the most common malignant tumor. Insulinoma is the most common pediatric pancreatic tumor of the endocrine pancreas. Malignant tumors require a complete, often radical, surgical resection. However, pancreatic parenchyma-sparing surgical procedures are utilized for benign tumors and low-grade malignancy to preserve gland function. This review will discuss the epidemiology, pathophysiology, clinical and diagnostic characteristics, and management options associated with both common and rare solid pancreatic masses in children. We will also discuss current challenges encountered in their evaluation and treatment.

1 November 2019 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
MBMelena D. Bellin
Melena D. Bellin
MLMark Lowe
Mark Lowe
MZM. Bridget Zimmerman
M. Bridget Zimmerman
MWMichael Wilschanski
Michael Wilschanski
SWSteven Werlin
Steven Werlin
AUAliye Uc
Aliye Uc
Objectives: Adults with chronic pancreatitis (CP) have a high risk for developing pancreatogenic diabetes mellitus (DM), but little is known regarding potential risk factors for DM in children with acute recurrent pancreatitis (ARP) or CP. We compared demographic and clinical features of children with ARP or CP, with and without DM, in the INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE (INSPPIRE) registry.Methods: We reviewed the INSPPIRE database for the presence or absence of physician‐diagnosed DM in 397 children, excluding those with total pancreatectomy with islet autotransplantation, enrolled from August 2012 to August 2017. Patient demographics, BMI percentile, age at disease onset, disease risk factors, disease burden, and treatments were compared between children with DM (n = 24) and without DM (n = 373).Results: Twenty‐four children (6% of the cohort) had a diagnosis of DM. Five of 13 tested were positive for beta cell autoantibodies. The DM group was 4.2 years [95% confidence interval (CI) 3–5.4] older at first episode of acute pancreatitis, and tended to more often have hypertriglyceridemia [odds ratio (OR) 5.21 (1.33–17.05)], coexisting autoimmune disease [OR 3.94 (0.88–13.65)] or pancreatic atrophy [OR 3.64 (1.13, 11.59)].Conclusion: Pancreatic atrophy may be more common among children with DM, suggesting more advanced exocrine disease. However, data in this exploratory cohort also suggest increased autoimmunity and hypertriglyceridemia in children with DM, suggesting that risk factors for type 1 and type 2 DM, respectively may play a role in mediating DM development in children with pancreatitis.